中国临床药理学杂志2025，Vol.41Issue(18)：2630-2634,5.DOI:10.13699/j.cnki.1001-6821.2025.18.010
醋酸阿托西班联合硫酸镁对早产抑制宫缩的临床研究
Clinical trial of atrosiban acetate combined with magnesium sulfate in inhibiting uterine contractions in premature delivery
摘要
Abstract
Objective To study the clinical effect and safety of atosiban acetate injection combined with magnesium sulfate injection in inhibiting uterine contractions in premature delivery.Methods Patients with threatened preterm delivery were divided into treatment group(treated with atosiban acetate combined with magnesium sulfate)and control group(treated with magnesium sulfate)by random number table method.The 24 h dose magnesium sulfate injection was 30 g and this drug was stopped when uterine contraction was inhibited,the total dose of atosiban acetate injection was≤330 mg and total treatment time should not exceed 48 h.The effects of contraction inhibition,serological indexes,hemodynamics,safety and perinatal outcomes of the two groups were compared.Results A total of 97 cases were screened in this study,there were 47 cases in control group and 45 cases in treatment group.The treatment group and control group with success rate of fetal protection were 97.78％and 82.98％,the extended gestation time was(26.35±4.12)and(20.04±3.27)d,and the onset time of uterine contraction was(1.58±0.26)and(2.45±0.38)h,and the difference was all statistically significant(all P＜0.05).After treatment,the interleukin-6(IL-6)levels in treatment group and control group were(142.34±15.75)and(182.17±19.43)ng·L-1,respectively.Matrix metalloproteinase inhibitor-1(TIMP-1)was(135.29±15.42)and(112.48±13.55)pg·mL-1,nitric oxide(NO)was(23.03±2.17)and(28.13±3.01)μmol·L-1;and the difference of the indexes between two groups was statistically significant(P＜0.05).After treatment,there were no statistically significant differences in systolic blood pressure(SBP)[(120.07±13.97)vs.(119.28±13.51)mmHg],heart rate(HR)[(93.56±10.82)vs.(93.32±10.65)bpm]and diastolic blood pressure(DBP)[(77.22±9.05)vs.(78.32±9.47)mmHg]between 2 groups(P＞0.05).There were no statistically differences in perinatal mortality and incidence of adverse reactions in 2 groups(P＞0.05).The incidence of neonatal asphyxia in treatment group and control group was 2.22％and 17.02％,and the incidence of low body weight infants was 2.22％and 14.89％,the difference was statistically significant(P＜0.05).Conclusion Atosiban acetate injection combined with magnesium sulfate injection can effectively inhibit uterine contraction,reduce inflammation,improve vascular endothelial function,regulate serum TIMP-1 expression,and improve perinatal outcomes in patients with threatened preterm delivery,with good safety and no significant effects on hemodynamics.关键词
醋酸阿托西班注射液/硫酸镁注射液/先兆早产/宫缩/母婴安全Key words
atosiban acetate injection/magnesium sulfate injection/threatened preterm birth/contractions/mother and child safety分类
药学引用本文复制引用
赵静,任志菲,贾高妍,张广意..醋酸阿托西班联合硫酸镁对早产抑制宫缩的临床研究[J].中国临床药理学杂志,2025,41(18):2630-2634,5.基金项目
宁夏回族自治区重点研发计划基金资助项目(2021BEG03041) （2021BEG03041）
